The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

If there’s a diet, Janet McCaskill says, she’s done it. “I’ve tried WeightWatchers. I’ve tried keto. I’ve gone to a ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic disorder X-linked adrenoleukodystrophy, or X-ALD.